The prevalence of asthma is increasing in- many countries,1 and there is evidence to suggest that associated mortality is increasing as well.2 The causes for the rise in the incidence of asthma are not entirely clear,2 as primary preventive measures have not yet been established. The reduction of mortality and morbidity depends largely on adequate and effective secondary prevention, treatment of an acute attack and control of chronic symptoms. It is therefore important to assess the adequacy of such treatment in the private sector, because of its significant contribution to the health care of the population, and especially since there is no on-site specialist supervision. This audit was an attempt to perform such an assessment.